Baptist Memorial Hospital–Attala is expanding access to cancer care and other outpatient treatments through its Infusion ...
The Brighterside of News on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Many patients endure hours-long infusions because antibody doses can exceed 100 milliliters, far beyond subcutaneous limits ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...
HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
And for patients facing extreme limitations to mobility, or who live vast distances from hospitals and clinics, mobile ...
Chennai: Caplin Steriles, a Subsidiary Company of Caplin Point Laboratories, has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug ...
Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback